

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

**Section 1: Identification**

Product name : Doramectin Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908  
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800 CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**Section 2: Hazard identification****GHS Classification**

Reproductive toxicity : Category 1

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Central nervous system, Liver, Kidney)

Hazardous to the aquatic environment - acute hazard : Category 1

Hazardous to the aquatic environment - chronic hazard : Category 1

**GHS label elements**

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.

## Doramectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

H371 May cause damage to organs (Central nervous system) if swallowed.

H373 May cause damage to organs (Central nervous system, Liver, Kidney) through prolonged or repeated exposure if swallowed.

H410 Very toxic to aquatic life with long lasting effects.

## Precautionary statements

: **Prevention:**

P201 Obtain special instructions before use.

P260 Do not breathe mist or vapours.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.

P391 Collect spillage.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**Section 3: Composition/information on ingredients**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Doramectin	117704-25-3	>= 1 -< 2.5

**Section 4: First-aid measures**

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention.

## Doramectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

	Wash clothing before reuse.
	Thoroughly clean shoes before reuse.
In case of eye contact	: Flush eyes with water as a precaution.
	Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting.
	Get medical attention.
	Rinse mouth thoroughly with water.
	Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	: May damage the unborn child.
	May cause damage to organs if swallowed.
	May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

---

**Section 5: Fire-fighting measures**

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Hazchem Code	: 3Z

---

**Section 6: Accidental release measures**

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment.

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
8.0	14.04.2025	5191219-00016	24.02.2025
			Date of first issue: 22.10.2019

---

Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**Section 7: Handling and storage**

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
Conditions for safe storage	:	Keep in properly labelled containers. Store locked up. Keep tightly closed.

## Doramectin Formulation

Version 8.0      Revision Date: 14.04.2025      SDS Number: 5191219-00016      Date of last issue: 24.02.2025  
Date of first issue: 22.10.2019

Materials to avoid : Store in accordance with the particular national regulations.  
: Do not store with the following product types:  
Strong oxidizing agents

## Section 8: Exposure controls/personal protection

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Doramectin	117704-25-3	TWA	35 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	350 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

## Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

## Section 9: Physical and chemical properties

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

Appearance	:	oily
Colour	:	light yellow
Odour	:	characteristic
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	-7 °C
Initial boiling point and boiling range	:	270 °C
Flash point	:	215.7 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	0.89 - 91
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	practically insoluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	31.7 - 32.1 m <sup>2</sup> /s ( 25 °C)
Explosive properties	:	Not explosive

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

---

**Section 10: Stability and reactivity**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**Section 11: Toxicological information**

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--------------------------------------------------------

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
---------------------	---	----------------------------------------------------------------------

**Components:****Doramectin:**

Acute oral toxicity	:	LD50 (Rat): 500 mg/kg Target Organs: Central nervous system
		LD50 (Mouse): > 2,000 mg/kg Target Organs: Central nervous system
		LD50 (Rat): 50 mg/kg Target Organs: Central nervous system
		LD50 (Mouse): 75 mg/kg Target Organs: Central nervous system
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 300 mg/kg Application Route: Intraperitoneal Target Organs: Central nervous system

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

**II****Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Doramectin:**

Genotoxicity in vitro	:	Test Type: Ames test Result: negative
		Test Type: Mouse Lymphoma Result: negative
		Test Type: unscheduled DNA synthesis assay Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Components:****Doramectin:**

Carcinogenicity - Assessment	:	Weight of evidence does not support classification as a carcinogen
------------------------------	---	--------------------------------------------------------------------

**Reproductive toxicity**

May damage the unborn child.



**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

**Components:****Doramectin:**

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: NOAEL: 0.3 mg/kg body weight Symptoms: Reduced body weight
	Test Type: Embryo-foetal development Species: Mouse Application Route: Oral Embryo-foetal toxicity: NOAEL: 3 mg/kg body weight Symptoms: Embryolethal effects
	Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral General Toxicity Maternal: NOAEL: 0.75 mg/kg body weight Symptoms: Maternal effects, Embryotoxic effects.
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

May cause damage to organs (Central nervous system) if swallowed.

**Components:****Doramectin:**

Exposure routes	: Oral
Target Organs	: Central nervous system
Assessment	: Shown to produce significant health effects in animals at concentrations of 300 mg/kg bw or less.

**STOT - repeated exposure**

May cause damage to organs (Central nervous system, Liver, Kidney) through prolonged or repeated exposure if swallowed.

**Components:****Doramectin:**

Exposure routes	: Oral
Target Organs	: Central nervous system, Liver, Kidney
Assessment	: Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

**Repeated dose toxicity****Components:****Doramectin:**

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

Species	: Rat
LOAEL	: 30 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Central nervous system

Species	: Rat
NOAEL	: 2 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Central nervous system, Liver, Kidney

Species	: Dog
NOAEL	: 2 mg/kg
Application Route	: Oral
Exposure time	: 36 d
Target Organs	: Eye
Symptoms	: Dilatation of the pupil

Species	: Dog
NOAEL	: 0.1 mg/kg
Application Route	: Oral
Exposure time	: 92 d
Target Organs	: Central nervous system, Eye
Symptoms	: Dilatation of the pupil

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Doramectin:**

Skin contact	: Target Organs: Gastro-intestinal system
	Symptoms: Nausea, Diarrhoea
	Target Organs: Central nervous system
	Symptoms: Dizziness, Headache
	Target Organs: Eye
	Symptoms: Irritation
	Target Organs: Skin
	Symptoms: Irritation
	Target Organs: Respiratory system
	Symptoms: Breathing difficulties
Ingestion	: Target Organs: Gastro-intestinal system
	Symptoms: Nausea, Abdominal pain, Diarrhoea
	Target Organs: Central nervous system
	Symptoms: Dizziness

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

**Section 12: Ecological information****Ecotoxicity****Components:****Doramectin:**

Toxicity to fish	:	LC50 (Lepomis macrochirus (Bluegill sunfish)): 11 µg/l Exposure time: 96 h Method: OECD Test Guideline 203
		LC50 (Oncorhynchus mykiss (rainbow trout)): 5.1 µg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.1 µg/l Exposure time: 48 h Method: OECD Test Guideline 202
M-Factor (Chronic aquatic toxicity)	:	10,000

**Ecotoxicology Assessment**

Acute aquatic toxicity	:	Very toxic to aquatic life.
------------------------	---	-----------------------------

**Persistence and degradability**

No data available

**Bioaccumulative potential****Components:****Doramectin:**

Bioaccumulation	:	Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 71 Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water	:	log Pow: 4.5 pH: 7

**Mobility in soil****Components:****Doramectin:**

Distribution among environmental compartments	:	log Koc: 4.94
-----------------------------------------------	---	---------------

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

**Other adverse effects****Components:****Doramectin:**

Results of PBT and vPvB assessment	:	Substance is not very persistent and very bioaccumulative (vPvB).
------------------------------------	---	-------------------------------------------------------------------

---

**Section 13: Disposal considerations****Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

**Section 14: Transport information****International Regulations****UNRTDG**

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Doramectin)
Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes

**IATA-DGR**

UN/ID No.	:	UN 3082
Proper shipping name	:	Environmentally hazardous substance, liquid, n.o.s. (Doramectin)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	964
Packing instruction (passenger aircraft)	:	964
Environmentally hazardous	:	yes

**IMDG-Code**

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Doramectin)
Class	:	9
Packing group	:	III
Labels	:	9

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

EmS Code : F-A, S-F  
Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****NZS 5433**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Doramectin)  
Class : 9  
Packing group : III  
Labels : 9  
Hazchem Code : 3Z  
Marine pollutant : no

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

**Section 15: Regulatory information****Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

**HSW Controls**

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

**The components of this product are reported in the following inventories:**

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

**Section 16: Other information**

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

Revision Date : 14.04.2025

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

**Full text of other abbreviations**

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

## Doramectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
8.0	14.04.2025	5191219-00016	Date of first issue: 22.10.2019

---

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN